PMID- 30546433
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200929
IS  - 1792-1074 (Print)
IS  - 1792-1082 (Electronic)
IS  - 1792-1074 (Linking)
VI  - 16
IP  - 6
DP  - 2018 Dec
TI  - Treatment of metastatic non-small cell lung cancer with NY-ESO-1 specific TCR 
      engineered-T cells in a phase I clinical trial: A case report.
PG  - 6998-7007
LID - 10.3892/ol.2018.9534 [doi]
AB  - This article presented a case of a human leukocyte antigen (HLA)-A2-positive 
      patient with advanced cancer/testis antigen New York esophageal squamous cell 
      carcinoma-1 (NY-ESO-1) expressing lung adenocarcinoma (LADC) who received 
      adoptive cell therapy of T cell receptor engineered-T cells (TCR-T cells) 
      targeting the cancer-testis antigen NY-ESO-1. The appropriate clinical and 
      laboratory assessments were conducted to investigate the safety and efficacy of 
      this therapy for this lung cancer patient. The patient had a clinical response to 
      and was well-tolerated with this therapy in the clinical trial. In addition, a 
      preliminary evaluation of the safety of NY-ESO-1 TCR-T cell therapy was performed 
      in four patients with non-small cell lung cancer (NSCLC) enrolled in a clinical 
      trial. It was well-tolerated and did not observe any serious adverse events 
      post-infusion. Fever, anemia, and a decrease in white blood cell count were 
      common adverse events, which were likely due to the TCR-T cell therapy. Two 
      patients had clinical responses to NY-ESO-1 TCR-T cell therapy, including the 
      44-year-old female patient with LADC, who achieved a short-term partial response 
      for 4 months, improved in Karnofsky performance status, and had a recovery of 
      drug sensitivity. This suggests that TCR-T cell therapy targeting NY-ESO-1 
      antigen may be beneficial for HLA-A2-positive late-stage patients with 
      NY-ESO-1-expressing NSCLC.
FAU - Xia, Yan
AU  - Xia Y
AD  - Department of Oncology, Shenzhen Second People's Hospital, The First Affiliated 
      Hospital of Shenzhen University, Shenzhen, Guangdong 518035, P.R. China.
AD  - Department of Research and Development, Shenzhen Institute for Innovation and 
      Translational Medicine, Shenzhen, Guangdong 518120, P.R. China.
AD  - Zhongshan School of Medicine, Sun Yat-Sen University, Guangzhou, Guangdong 
      510080, P.R. China.
FAU - Tian, Xiaopeng
AU  - Tian X
AD  - Zhongshan School of Medicine, Sun Yat-Sen University, Guangzhou, Guangdong 
      510080, P.R. China.
FAU - Wang, Juntao
AU  - Wang J
AD  - Department of Research and Development, Shenzhen Institute for Innovation and 
      Translational Medicine, Shenzhen, Guangdong 518120, P.R. China.
FAU - Qiao, Dongjuan
AU  - Qiao D
AD  - Department of Research and Development, Shenzhen Institute for Innovation and 
      Translational Medicine, Shenzhen, Guangdong 518120, P.R. China.
FAU - Liu, Xianhao
AU  - Liu X
AD  - Department of Oncology, Shenzhen Second People's Hospital, The First Affiliated 
      Hospital of Shenzhen University, Shenzhen, Guangdong 518035, P.R. China.
FAU - Xiao, Liang
AU  - Xiao L
AD  - Department of Oncology, Shenzhen Second People's Hospital, The First Affiliated 
      Hospital of Shenzhen University, Shenzhen, Guangdong 518035, P.R. China.
FAU - Liang, Wenli
AU  - Liang W
AD  - Department of Oncology, Shenzhen Second People's Hospital, The First Affiliated 
      Hospital of Shenzhen University, Shenzhen, Guangdong 518035, P.R. China.
FAU - Ban, Dongcheng
AU  - Ban D
AD  - Department of Research and Development, Shenzhen Institute for Innovation and 
      Translational Medicine, Shenzhen, Guangdong 518120, P.R. China.
FAU - Chu, Junjun
AU  - Chu J
AD  - Zhongshan School of Medicine, Sun Yat-Sen University, Guangzhou, Guangdong 
      510080, P.R. China.
FAU - Yu, Jiaming
AU  - Yu J
AD  - Zhongshan School of Medicine, Sun Yat-Sen University, Guangzhou, Guangdong 
      510080, P.R. China.
FAU - Wang, Rongfu
AU  - Wang R
AD  - Center for Inflammation and Epigenetics, Houston Methodist Research Institute, 
      Houston, TX 77030, USA.
FAU - Tian, Geng
AU  - Tian G
AD  - Department of Oncology, Shenzhen Second People's Hospital, The First Affiliated 
      Hospital of Shenzhen University, Shenzhen, Guangdong 518035, P.R. China.
FAU - Wang, Mingjun
AU  - Wang M
AD  - Department of Research and Development, Shenzhen Institute for Innovation and 
      Translational Medicine, Shenzhen, Guangdong 518120, P.R. China.
LA  - eng
PT  - Journal Article
DEP - 20181001
PL  - Greece
TA  - Oncol Lett
JT  - Oncology letters
JID - 101531236
PMC - PMC6256329
OTO - NOTNLM
OT  - NY-ESO-1
OT  - TCR-engineered T cell
OT  - adoptive cell therapy
OT  - lung adenocarcinoma
OT  - non-small cell lung cancer
EDAT- 2018/12/14 06:00
MHDA- 2018/12/14 06:01
PMCR- 2018/10/01
CRDT- 2018/12/15 06:00
PHST- 2018/02/13 00:00 [received]
PHST- 2018/07/27 00:00 [accepted]
PHST- 2018/12/15 06:00 [entrez]
PHST- 2018/12/14 06:00 [pubmed]
PHST- 2018/12/14 06:01 [medline]
PHST- 2018/10/01 00:00 [pmc-release]
AID - OL-0-0-9534 [pii]
AID - 10.3892/ol.2018.9534 [doi]
PST - ppublish
SO  - Oncol Lett. 2018 Dec;16(6):6998-7007. doi: 10.3892/ol.2018.9534. Epub 2018 Oct 1.